Literature DB >> 22969875

Investigation of FJ 194940.1 gene alternative splicing in colon cancer and its association with clinicopathological parameters.

Malwina Bartczak-Tomczyk1, Aleksandra Sałagacka, Marek Mirowski, Ewa Balcerczak.   

Abstract

Colorectal cancer (CRC) is one of the most frequent neoplasms and is responsible for the second highest mortality rate of all cancers in the more developed regions of the world. The molecular mechanisms of CRC are relatively well characterized and are correlated to the accumulation of genetic mutations and certain patterns of gene expression/over-expression. There are a number of possible molecular factors involved in CRC progression in the aforementioned pathways, which are as yet not well described. One of these factors appears to be the gene FJ 194940.1, previously termed P65. FJ 194940.1 consists of 6 exons and probably undergoes alternative splicing in malignant tissues. In this study, tissue samples from 102 patients with colon cancer were investigated to confirm alternative splicing and to correlate results obtained with clinicopathological parameters. A total of 18 splice variants, which arise from various combinations of 4 exons (II, III, IV and V) and exon-exon junctions between exons 1 and 2 (I/II); 2 and 3 (II/III); 3 and 4 (III/IV), as well as 4 and 5 (IV/V), were found. For statistical analysis the full length transcript was divided into parts A and B. Part A consisted of exons II and III, as well as I/II and II/III exon-exon junctions, whereas part B comprised exons IV and V, as well as III/IV and IV/V exon-exon junctions. The expression of part B of the FJ 194940.1 gene transcript is correlated with well-differentiated (G1) and moderately differentiated cases (G2). Lymphocytic tumor infiltration, a good prognostic factor in CRC, was significantly correlated to the presence of all elements in part A of the FJ 194940.1 gene transcript. Patients who had all elements in part A of the transcript survived for a shorter duration. Investigation of the FJ 194940.1 gene revealed that the gene had undergone alternative splicing. However, the role of its transcripts and potential proteins should be examined in detail.

Entities:  

Year:  2011        PMID: 22969875      PMCID: PMC3438635          DOI: 10.3892/etm.2011.378

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  15 in total

1.  Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function.

Authors:  S M Hewitt; G F Saunders
Journal:  Anticancer Res       Date:  1996 Mar-Apr       Impact factor: 2.480

2.  Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines.

Authors:  T I Orban; E Olah
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

3.  CD44V6 in gastric carcinoma: a marker of tumor progression.

Authors:  Y Xin; A Grace; M M Gallagher; B T Curran; M B Leader; E W Kay
Journal:  Appl Immunohistochem Mol Morphol       Date:  2001-06

4.  Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer.

Authors:  S Aaltomaa; P Lipponen; M Ala-Opas; V M Kosma
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

5.  Splice variant expression of CD44 in patients with breast and ovarian cancer.

Authors:  M Sanchez Lockhart; S E Hajos; F M Basilio; C Mongini; E Alvarez
Journal:  Oncol Rep       Date:  2001 Jan-Feb       Impact factor: 3.906

6.  Expression of gene encoding P65 oncofetal protein in acute and chronic leukemias.

Authors:  E Balcerczak; J Bartkowiak; J Z Błoński; T Robak; M Mirowski
Journal:  Neoplasma       Date:  2002       Impact factor: 2.575

7.  Expression of C-ERBB2 and P65 genes and their protein products in follicular neoplasms of thyroid gland.

Authors:  W Czyz; E Balcerczak; M Rudowicz; H Niewiadomska; Z Pasieka; K Kuzdak; M Mirowski
Journal:  Folia Histochem Cytobiol       Date:  2003       Impact factor: 1.698

8.  The role of CD44v3 expression in female breast carcinomas.

Authors:  Janusz Ryś; Anna Kruczak; Bozena Lackowska; Agnieszka Jaszcz-Gruchała; Anna Brandys; Andrzej Stelmach; Marian Reinfuss
Journal:  Pol J Pathol       Date:  2003       Impact factor: 1.072

9.  Quantitative analysis of the p65 gene expression in patients with coloroctal cancer.

Authors:  E Balcerczak; M Balcerczak; M Mirowski
Journal:  Int J Biomed Sci       Date:  2007-12

10.  WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.

Authors:  C Englert; X Hou; S Maheswaran; P Bennett; C Ngwu; G G Re; A J Garvin; M R Rosner; D A Haber
Journal:  EMBO J       Date:  1995-10-02       Impact factor: 11.598

View more
  1 in total

1.  Quantitative analysis of FJ 194940.1 gene expression in colon cancer and its association with clinicopathological parameters.

Authors:  Malwina Bartczak-Tomczyk; Aleksandra Sałagacka; Marek Mirowski; Agnieszka Jeleń; Ewa Balcerczak
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.